Titre : Personnel de recherche

Personnel de recherche : Questions médicales fréquentes

Termes MeSH sélectionnés :

Interrupted Time Series Analysis
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Personnel de recherche : Questions médicales les plus fréquentes", "headline": "Personnel de recherche : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Personnel de recherche : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-07", "dateModified": "2025-04-01", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Personnel de recherche" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Groupes professionnels", "url": "https://questionsmedicales.fr/mesh/D009274", "about": { "@type": "MedicalCondition", "name": "Groupes professionnels", "code": { "@type": "MedicalCode", "code": "D009274", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "M01.526" } } }, "about": { "@type": "MedicalCondition", "name": "Personnel de recherche", "alternateName": "Research Personnel", "code": { "@type": "MedicalCode", "code": "D012108", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "I L Krom", "url": "https://questionsmedicales.fr/author/I%20L%20Krom", "affiliation": { "@type": "Organization", "name": "The Federal State Budget Educational Institution of Higher Education \"The V. I. Razumovsky Saratov State Medical University\" of Minzdrav of Russia, 410012, Saratov, Russia, irina.crom@yandex.ru." } }, { "@type": "Person", "name": "M V Erugina", "url": "https://questionsmedicales.fr/author/M%20V%20Erugina", "affiliation": { "@type": "Organization", "name": "The Federal State Budget Educational Institution of Higher Education \"The V. I. Razumovsky Saratov State Medical University\" of Minzdrav of Russia, 410012, Saratov, Russia." } }, { "@type": "Person", "name": "Luellen Fletcher", "url": "https://questionsmedicales.fr/author/Luellen%20Fletcher", "affiliation": { "@type": "Organization", "name": "Perelman School of Medicine Path BioResource University of Pennsylvania M163 John Morgan Bldg., 3620 Hamilton WalkPhiladelphiaPennsylvania19104 USA." } }, { "@type": "Person", "name": "Christina A Harrington", "url": "https://questionsmedicales.fr/author/Christina%20A%20Harrington", "affiliation": { "@type": "Organization", "name": "University Shared Resources and Knight Cancer Institute Oregon Health & Science University 3181 S.W. Sam Jackson Park RoadPortlandOregon97239 USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Admissions to psychiatric inpatient services and use of coercive measures in 2020 in a Swiss psychiatric department: An interrupted time-series analysis.", "datePublished": "2023-07-27", "url": "https://questionsmedicales.fr/article/37498908", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0289310" } }, { "@type": "ScholarlyArticle", "name": "National COVID-19 lockdown and trends in help-seeking for violence against children in Zimbabwe: an interrupted time-series analysis.", "datePublished": "2022-11-18", "url": "https://questionsmedicales.fr/article/36401183", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12889-022-14425-w" } }, { "@type": "ScholarlyArticle", "name": "Delayed Diagnosis and Treatment of Cancer Patients During the COVID-19 Pandemic in Henan, China: An Interrupted Time Series Analysis.", "datePublished": "2022-05-24", "url": "https://questionsmedicales.fr/article/35685763", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpubh.2022.881718" } }, { "@type": "ScholarlyArticle", "name": "Impact of COVID-19 on poisoning-related mortality in Iran: An interrupted time series study.", "datePublished": "2023-05-05", "url": "https://questionsmedicales.fr/article/37182353", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.drugpo.2023.104051" } }, { "@type": "ScholarlyArticle", "name": "Multiple impacts of the COVID-19 pandemic and antimicrobial stewardship on antimicrobial resistance in nosocomial infections: an interrupted time series analysis.", "datePublished": "2024-07-17", "url": "https://questionsmedicales.fr/article/39086796", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpubh.2024.1419344" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Personnes", "item": "https://questionsmedicales.fr/mesh/D009272" }, { "@type": "ListItem", "position": 3, "name": "Groupes professionnels", "item": "https://questionsmedicales.fr/mesh/D009274" }, { "@type": "ListItem", "position": 4, "name": "Personnel de recherche", "item": "https://questionsmedicales.fr/mesh/D012108" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Personnel de recherche - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Personnel de recherche", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-18", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Personnel de recherche", "description": "Comment évaluer l'efficacité d'un traitement ?\nQuelles méthodes de recherche sont utilisées ?\nComment identifier les biais dans une étude ?\nQu'est-ce qu'une revue systématique ?\nComment mesurer la validité d'un test ?", "url": "https://questionsmedicales.fr/mesh/D012108?mesh_terms=Interrupted+Time+Series+Analysis&page=9#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Personnel de recherche", "description": "Quels symptômes surveiller lors d'une étude ?\nComment évaluer les effets secondaires ?\nQuels indicateurs de santé sont mesurés ?\nComment documenter les symptômes des participants ?\nQuelle est l'importance des auto-évaluations ?", "url": "https://questionsmedicales.fr/mesh/D012108?mesh_terms=Interrupted+Time+Series+Analysis&page=9#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Personnel de recherche", "description": "Quelles stratégies de prévention sont utilisées ?\nComment évaluer l'impact des programmes de prévention ?\nQuels facteurs influencent la prévention ?\nComment sensibiliser à la prévention ?\nQuelle est l'importance du dépistage précoce ?", "url": "https://questionsmedicales.fr/mesh/D012108?mesh_terms=Interrupted+Time+Series+Analysis&page=9#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Personnel de recherche", "description": "Comment choisir un traitement dans une étude ?\nQuelles sont les approches de traitement courantes ?\nComment évaluer l'adhérence au traitement ?\nQuels sont les critères d'évaluation des traitements ?\nComment gérer les traitements combinés ?", "url": "https://questionsmedicales.fr/mesh/D012108?mesh_terms=Interrupted+Time+Series+Analysis&page=9#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Personnel de recherche", "description": "Quelles complications peuvent survenir dans les études ?\nComment gérer les complications dans une étude ?\nQuels sont les risques associés aux traitements ?\nComment évaluer les complications post-traitement ?\nQuelle est l'importance de la déclaration des complications ?", "url": "https://questionsmedicales.fr/mesh/D012108?mesh_terms=Interrupted+Time+Series+Analysis&page=9#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Personnel de recherche", "description": "Quels sont les facteurs de risque courants ?\nComment identifier les facteurs de risque dans une étude ?\nQuel rôle joue l'environnement dans les risques ?\nComment évaluer l'impact des facteurs de risque ?\nQuelle est l'importance de la prévention des risques ?", "url": "https://questionsmedicales.fr/mesh/D012108?mesh_terms=Interrupted+Time+Series+Analysis&page=9#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment évaluer l'efficacité d'un traitement ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité est évaluée par des études cliniques contrôlées et des analyses statistiques." } }, { "@type": "Question", "name": "Quelles méthodes de recherche sont utilisées ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les méthodes incluent les essais randomisés, les études de cohorte et les méta-analyses." } }, { "@type": "Question", "name": "Comment identifier les biais dans une étude ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les biais peuvent être identifiés par l'examen des méthodes de sélection et d'analyse des données." } }, { "@type": "Question", "name": "Qu'est-ce qu'une revue systématique ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "C'est une synthèse des études existantes sur un sujet, évaluant la qualité des preuves." } }, { "@type": "Question", "name": "Comment mesurer la validité d'un test ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "La validité est mesurée par la sensibilité, la spécificité et la valeur prédictive." } }, { "@type": "Question", "name": "Quels symptômes surveiller lors d'une étude ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient selon l'étude, mais incluent souvent douleur, fatigue et dysfonction." } }, { "@type": "Question", "name": "Comment évaluer les effets secondaires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires sont évalués par des questionnaires et des rapports de patients." } }, { "@type": "Question", "name": "Quels indicateurs de santé sont mesurés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les indicateurs incluent la pression artérielle, le taux de cholestérol et les marqueurs biologiques." } }, { "@type": "Question", "name": "Comment documenter les symptômes des participants ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes sont documentés par des journaux de santé et des évaluations cliniques régulières." } }, { "@type": "Question", "name": "Quelle est l'importance des auto-évaluations ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les auto-évaluations fournissent des informations précieuses sur l'état de santé perçu par le patient." } }, { "@type": "Question", "name": "Quelles stratégies de prévention sont utilisées ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les stratégies incluent l'éducation, les vaccinations et les dépistages réguliers." } }, { "@type": "Question", "name": "Comment évaluer l'impact des programmes de prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "L'impact est évalué par des études de suivi et des analyses de données de santé publique." } }, { "@type": "Question", "name": "Quels facteurs influencent la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'accès aux soins, le niveau d'éducation et les comportements de santé." } }, { "@type": "Question", "name": "Comment sensibiliser à la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "La sensibilisation se fait par des campagnes d'information, des ateliers et des médias sociaux." } }, { "@type": "Question", "name": "Quelle est l'importance du dépistage précoce ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Le dépistage précoce permet d'identifier les maladies à un stade précoce, améliorant les résultats." } }, { "@type": "Question", "name": "Comment choisir un traitement dans une étude ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le choix est basé sur des critères d'inclusion, des protocoles et des résultats antérieurs." } }, { "@type": "Question", "name": "Quelles sont les approches de traitement courantes ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les approches incluent la pharmacothérapie, la thérapie physique et les interventions chirurgicales." } }, { "@type": "Question", "name": "Comment évaluer l'adhérence au traitement ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "L'adhérence est évaluée par des questionnaires, des entretiens et des suivis réguliers." } }, { "@type": "Question", "name": "Quels sont les critères d'évaluation des traitements ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les critères incluent l'efficacité, la sécurité, la tolérance et la qualité de vie." } }, { "@type": "Question", "name": "Comment gérer les traitements combinés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements combinés nécessitent une évaluation rigoureuse des interactions et des effets cumulés." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir dans les études ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des effets indésirables, des non-conformités et des biais d'étude." } }, { "@type": "Question", "name": "Comment gérer les complications dans une étude ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "La gestion implique une surveillance étroite, des ajustements de protocole et des rapports transparents." } }, { "@type": "Question", "name": "Quels sont les risques associés aux traitements ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les risques incluent des réactions allergiques, des interactions médicamenteuses et des complications chirurgicales." } }, { "@type": "Question", "name": "Comment évaluer les complications post-traitement ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les complications sont évaluées par des suivis cliniques et des questionnaires de satisfaction." } }, { "@type": "Question", "name": "Quelle est l'importance de la déclaration des complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La déclaration permet d'améliorer la sécurité des patients et d'affiner les protocoles de recherche." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque courants ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, le sexe, les antécédents médicaux et les habitudes de vie." } }, { "@type": "Question", "name": "Comment identifier les facteurs de risque dans une étude ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs sont identifiés par des questionnaires, des entretiens et des analyses de données." } }, { "@type": "Question", "name": "Quel rôle joue l'environnement dans les risques ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "L'environnement influence les risques par l'exposition à des toxines, des infections et des comportements." } }, { "@type": "Question", "name": "Comment évaluer l'impact des facteurs de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "L'impact est évalué par des études épidémiologiques et des analyses statistiques." } }, { "@type": "Question", "name": "Quelle est l'importance de la prévention des risques ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "La prévention réduit l'incidence des maladies et améliore la santé publique globale." } } ] } ] }

Sources (10000 au total)

Admissions to psychiatric inpatient services and use of coercive measures in 2020 in a Swiss psychiatric department: An interrupted time-series analysis.

The CoVID pandemic and the associated lockdown had a significant impact on mental health services. Inpatient services faced the challenge of offering acute psychiatric while implementing strict infect... To investigate the effects of the CoVID outbreak on psychiatric admissions, use of seclusion and symptom severity.... Using routine data from 2019 and 2020 gathered in the Department of Psychiatry at the Geneva University Hospitals, we performed an interrupted time series analysis. This included the number of psychia... Hospitalizations decreased over time (b = -0.57, 95% CI: -0.67; -0.48, p < .001). A structural break in the data (supremum Wald test: p < .001) was observed in the 12th week of 2020. There was an inve... Our results show that the CoVID pandemic in 2020 was associated with a significant decrease in the number of hospital admissions. This decrease was correlated with a greater use of seclusion. The high...

National COVID-19 lockdown and trends in help-seeking for violence against children in Zimbabwe: an interrupted time-series analysis.

An estimated 1.8 billion children live in countries where COVID-19 disrupted violence prevention and response. It is important to understand how government policies to contain COVID-19 impacted childr... We used an interrupted time series design to analyse the proportion of violence related calls (17,913 calls out of 57,050) to Childline Zimbabwe's national child helpline between 2017 to 2021. We appl... The proportion of violence related calls decreased in the 90 days after the lockdown and subsequently returned to pre-COVID-19 levels. We estimate that 10.3% (95% confidence interval [CI] 6.0-14.6%) m... Lockdowns dramatically change everyday life and strain populations, which is unlikely to reduce violence prevalence but may reduce help-seeking. The three months after COVID-19 lockdowns may be key ti...

Delayed Diagnosis and Treatment of Cancer Patients During the COVID-19 Pandemic in Henan, China: An Interrupted Time Series Analysis.

To investigate the possible impact of lockdown policies on the diagnosis and treatment of cancer patients in Henan, China.... We collected data from the Henan Cancer Hospital, affiliated with Zhengzhou University. The monthly numbers of inpatient admissions from January 2014 to December 2019 were used to forecast the number ... For specific diagnoses, treatment modalities, and age groups, we compared the changes in monthly admissions after the pandemic with the forecasted changes from the model.... The observed overall monthly number of inpatient admissions decreased by 20.2% [95% confidence interval (CI), 11.7-27.2%], 78.9% (95% CI, 77.3-80.4%), and 40.9% (95% CI, 35.6-45.5%) in January, Februa... The COVID-19 pandemic has significantly delayed the diagnosis and treatment of cancer in Henan, China. Long-term research should be conducted to assess the future effects of lockdown policies....

Impact of COVID-19 on poisoning-related mortality in Iran: An interrupted time series study.

The COVID-19 pandemic had many negative effects worldwide. These effects involved mental health status issues such as suicide, depression, and the pattern of death associated with drug/poisonings. One... The patients who died from six different categories of drugs or poisons were identified by forensic analysis of body fluids/tissues in Tehran, Iran. The pandemic was separated into the pre-COVID-19 pe... A total of 6,316 deaths from drugs/poisoning were identified between April 2018-Mar 2022). During this period, 2,485 deaths occurred pre-COVID, and 3,831 were during the COVID-19 era. There were no st... Changes in poisoning-related mortality patterns showed dramatic changes after the start of the pandemic, especially deaths from methanol. Other poisonings such as opioids, stimulants, and drugs should...

Multiple impacts of the COVID-19 pandemic and antimicrobial stewardship on antimicrobial resistance in nosocomial infections: an interrupted time series analysis.

The emergency response to the COVID-19 pandemic may disrupt hospital management activities of antimicrobial resistance (AMR). This study aimed to determine the changing AMR trend over the period in Ch... This retrospective study was conducted in a designated hospital for COVID-19 patients in Guangzhou, China from April 2018 to September 2021. The prevalence of 13 antimicrobial-resistant bacteria was c... A total of 10,134 isolates over 1,265 days were collected. And antimicrobial-resistant strains presented in 38.6% of the testing isolates. The weekly AMR prevalence decreased by 0.29 percentage point ... The response to COVID-19 did not lead to an increase in overall AMR; however, it appears that management strategy on the prudent use of antimicrobials likely contributed to a sizable long-term drop. T...

Impact of national drug price negotiation policy on the accessibility and utilization of PCSK9 inhibitors in China: an interrupted time series analysis.

PCSK9 inhibitors are a novel class of lipid-lowering drugs that have demonstrated favorable efficacy and safety. Evolocumab and alirocumab have been added to China's National Reimbursement Drug List t... The procurement data of evolocumab and alirocumab were collected from 1,519 hospitals between January 2021 and December 2022. We determined the monthly availability, utilization, cost per daily define... The NDPN policy led to a significant and sudden increase in the availability and utilization of PCSK9 inhibitors, along with a decrease in their DDDc. In the year following the policy implementation, ... The NDPN policy has successfully improved the accessibility and utilization of PCSK9 inhibitors in China. However, regional disparities in utilization indicate the need for further interventions to en...

Vulnerable road user injury trends following the COVID-19 pandemic in Toronto, Canada: An interrupted time series analysis.

The COVID-19 pandemic altered traffic patterns worldwide, potentially impacting pedestrian and bicyclists safety in urban areas. In Toronto, Canada, work from home policies, bicycle network expansion,... We used an interrupted time series design, with injury counts aggregated quarterly. We fit a negative binomial regression using a Bayesian modeling approach to data prior to the pandemic that included... There were 38% fewer pedestrian KSI (95%CI: 19%, 52%), 35% fewer ED visits (95%CI: 28%, 42%), and 19% fewer hospitalizations (95%CI: 2%, 32%) since the beginning of the COVID-19 pandemic. A reduction ... New road safety interventions during the pandemic may have improved road safety for vulnerable road users with respect to collisions with motor vehicles; however, further investigation into the risk f...

Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis.

To evaluate the impacts of the 2017 adjustment of National Reimbursement Drug List (NRDL) on orphan drugs hospital procurement volumes and spending in China.... We used an interrupted time series design covering the period from 2016 to 2018 to analyse changes in hospital procurement volumes and spending of orphan drugs for which were included in the 2017 NRDL... The study was conducted in China. Orphan drug procurement data of 789 public hospitals (594 tertiary hospitals and 195 secondary hospitals) were derived from the Chinese Medical Economic Information (... Monthly orphan drugs hospital procurement volumes and spending.... Nine orphan drugs were included in the 2017 NRDL (seven were directly included, and two were included after price negotiation). Comparing to orphan drugs not included in the NRDL, hospital procurement... Our results suggest that the 2017 adjustment of NRDL significantly changed the usage and spending on certain orphan drugs. The increase in orphan drug hospital procurement volumes should improve rare ...

Effectiveness of a Multi-component Delirium Prevention Program Implemented on General Medicine Hospital Units: an Interrupted Time Series Analysis.

Delirium is among the most prevalent harmful events in hospitals that is associated with an elevated risk for severe outcomes such as functional decline, falls, longer length of stay, and increased mo... To evaluate the impact of the implementation of a multi-component delirium program on the prevalence of delirium and the incidence of falls among patients staying on general medicine inpatient hospita... A pre-post intervention study using retrospective chart abstraction and interrupted time series analysis.... Patients were selected from adult patients that stayed at least 1 day on one of the five general medicine units in a large community hospital in Ontario, Canada. A total of 16 random samples of 50 pat... The delirium program included multiple components: education of staff and hospital leadership, twice per day bed-side screen for delirium, non-pharmacological and pharmacological prevention, and inter... Delirium prevalence was assessed using the evidence-based delirium chart abstraction method, CHART-del. Demographic data as well as fall incidence were also collected.... Our evaluation showed that the implementation of a multicomponent delirium program led to a reduction in delirium prevalence and fall incidences. The reduction in both delirium and falls was the large... A multi-component delirium program to improve the prevention, recognition, and management of delirium reduces the prevalence of delirium and fall incidence among patients in general medicine units....